IV iron isomaltoside vs oral iron
Serious adverse events ‐ remission or mild disease (8 weeks) · IBD patients
It is very uncertain whether IV iron isomaltoside changes serious adverse events ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
- Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyRR 4.02 [0.51, 31.73]1 study · 338 participantsVery low